New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

How do you modify HMA treatments for a patient with high-risk MDS experiencing prolonged cytopenias after each cycle?

What ANC and platelet thresholds do you use?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · The Robert Larner, M.D. College of Medicine at The University of Vermont
Answered on

When using azacitidine for the treatment of MDS, I adjust the dose in case of cytopenia for cycle 2 onwards.

  • If there was no baseline cytopenia (ANC >1.5, PLT >75K) but cytopenia developed with treatment, the subsequent cycle is delayed until counts recover, and the dose is based on the nadir and the time to recovery.
    • If nadir ANC <1 and PLT <50K but recovery is within 14 days, no adjustment is made and continue 28-day cycles.
    • If nadir ANC <1 or PLT <50K and recovery was longer than 14 days, t...

Join for free or sign in to see the full answer